Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Cloudy peritoneal dialysate: in search of a clear cause?

Fieren MW.

J Am Soc Nephrol. 2013 Dec;24(12):1929-31. doi: 10.1681/ASN.2013080911. Epub 2013 Oct 31. No abstract available.

2.
3.

Management of encapsulating peritoneal sclerosis: a guideline on optimal and uniform treatment.

Habib SM, Betjes MG, Fieren MW, Boeschoten EW, Abrahams AC, Boer WH, Struijk DG, Ruger W, Krikke C, Westerhuis R, de Sévaux RG, van der Sande FM, Gaasbeek A, Korte MR; Eps Registry.

Neth J Med. 2011 Nov-Dec;69(11):500-7. Review.

4.

Risk factors associated with encapsulating peritoneal sclerosis in Dutch EPS study.

Korte MR, Sampimon DE, Lingsma HF, Fieren MW, Looman CW, Zietse R, Weimar W, Betjes MG; Dutch Multicenter EPS Study.

Perit Dial Int. 2011 May-Jun;31(3):269-78. doi: 10.3747/pdi.2010.00167. Epub 2011 Mar 31.

PMID:
21454391
5.

Use of angiotensin II inhibitors in patients that develop encapsulating peritoneal sclerosis.

Sampimon DE, Kolesnyk I, Korte MR, Fieren MW, Struijk DG, Krediet RT.

Perit Dial Int. 2010 Nov-Dec;30(6):656-9. doi: 10.3747/pdi.2009.00201. No abstract available.

PMID:
21148060
6.

Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study.

Korte MR, Fieren MW, Sampimon DE, Lingsma HF, Weimar W, Betjes MG; investigators of the Dutch Multicentre EPS Study.

Nephrol Dial Transplant. 2011 Feb;26(2):691-7. doi: 10.1093/ndt/gfq362. Epub 2010 Jun 27.

PMID:
20584735
7.

Bioactive rather than total IGF-I is involved in acute responses to nutritional interventions in CAPD patients.

Brugts MP, Tjiong HL, Rietveld T, Wattimena JL, van den Berg JW, Fieren MW, Janssen JA.

Nephrol Dial Transplant. 2010 Mar;25(3):940-6. doi: 10.1093/ndt/gfp576. Epub 2009 Nov 9.

PMID:
19903658
8.

Amino Acid-based peritoneal dialysis solutions for malnutrition: new perspectives.

Tjiong HL, Swart R, van den Berg JW, Fieren MW.

Perit Dial Int. 2009 Jul-Aug;29(4):384-93. Review.

PMID:
19602603
9.

Dialysate as food as an option for automated peritoneal dialysis.

Tjiong HL, Swart R, Van den Berg JW, Fieren MW.

NDT Plus. 2008 Oct;1(Suppl 4):iv36-iv40. doi: 10.1093/ndtplus/sfn122.

10.

Whole-body protein turnover in peritoneal dialysis patients: a comparison of the [15N]glycine end product and the [13C]leucine precursor methods.

Tjiong HL, Swart R, Rietveld T, Wattimena JL, Hop WC, Fieren MW, van den Berg JW.

Nephrol Dial Transplant. 2008 Aug;23(8):2660-5. doi: 10.1093/ndt/gfn025. Epub 2008 Feb 28.

PMID:
18308773
11.

Peritoneal protein losses and cytokine generation in automated peritoneal dialysis with combined amino acids and glucose solutions.

Tjiong HL, Zijlstra FJ, Rietveld T, Wattimena JL, Huijmans JG, Swart GR, Fieren MW.

Mediators Inflamm. 2007;2007:97272. doi: 10.1155/2007/97272.

12.

Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment.

Heijns JB, van der Burg ME, van Gelder T, Fieren MW, de Bruijn P, van der Gaast A, Loos WJ.

Cancer Chemother Pharmacol. 2008 Oct;62(5):841-7. doi: 10.1007/s00280-007-0671-9. Epub 2008 Jan 19.

13.

Posttransplant encapsulating peritoneal sclerosis: a worrying new trend?

Fieren MW, Betjes MG, Korte MR, Boer WH.

Perit Dial Int. 2007 Nov-Dec;27(6):619-24. Review.

PMID:
17984419
14.

Peritoneal dialysis with solutions containing amino acids plus glucose promotes protein synthesis during oral feeding.

Tjiong HL, Rietveld T, Wattimena JL, van den Berg JW, Kahriman D, van der Steen J, Hop WC, Swart R, Fieren MW.

Clin J Am Soc Nephrol. 2007 Jan;2(1):74-80. Epub 2006 Nov 8.

15.

Albumin and whole-body protein synthesis respond differently to intraperitoneal and oral amino acids.

Tjiong HL, Fieren MW, Rietveld T, Wattimena JL, Schierbeek H, Huijmans JG, Hop WC, Swart GR, van den Berg JW.

Kidney Int. 2007 Aug;72(3):364-9. Epub 2007 Jun 6.

16.

Increasing incidence of severe encapsulating peritoneal sclerosis after kidney transplantation.

Korte MR, Yo M, Betjes MG, Fieren MW, van Saase JC, Boer WH, Weimar W, Zietse R.

Nephrol Dial Transplant. 2007 Aug;22(8):2412-4. Epub 2007 Mar 29. No abstract available.

PMID:
17395649
17.

Dialysate as food: combined amino acid and glucose dialysate improves protein anabolism in renal failure patients on automated peritoneal dialysis.

Tjiong HL, van den Berg JW, Wattimena JL, Rietveld T, van Dijk LJ, van der Wiel AM, van Egmond AM, Fieren MW, Swart R.

J Am Soc Nephrol. 2005 May;16(5):1486-93. Epub 2005 Mar 30.

18.

Persistent (not intermittent) nasal carriage of Staphylococcus aureus is the determinant of CPD-related infections.

Nouwen JL, Fieren MW, Snijders S, Verbrugh HA, van Belkum A.

Kidney Int. 2005 Mar;67(3):1084-92.

19.
20.

Yersinia pseudotuberculosis bacteraemia in a kidney transplant patient.

Van Zonneveld M, Droogh JM, Fieren MW, Gyssens IC, Van Gelder T, Weimar W.

Nephrol Dial Transplant. 2002 Dec;17(12):2252-4. No abstract available.

PMID:
12454242
22.

Peritonitis following endoscopic polypectomy in a peritoneal dialysis patient: the need for antibiotic prophylaxis.

Bac DJ, van Blankenstein M, de Marie S, Fieren MW.

Infection. 1994 May-Jun;22(3):220-1. Review. No abstract available.

PMID:
7927824
23.

Peritoneal macrophages from patients on continuous ambulatory peritoneal dialysis show a differential secretion of prostanoids and interleukin-1 beta.

Fieren MW, van den Bemd GJ, Bonta IL.

Prostaglandins Leukot Essent Fatty Acids. 1992 Sep;47(1):23-8.

PMID:
1438464
24.

Prostaglandin E2 inhibits the release of tumor necrosis factor-alpha, rather than interleukin 1 beta, from human macrophages.

Fieren MW, van den Bemd GJ, Ben-Efraim S, Bonta IL.

Immunol Lett. 1992 Jan;31(1):85-90.

PMID:
1548034
25.

Tumour necrosis factor in inflammation: relation to other mediators and to macrophage antitumour defence.

Bonta IL, Ben-Efraim S, Mózes T, Fieren MW.

Pharmacol Res. 1991 Aug;24(2):115-30. Review. No abstract available.

PMID:
1749743
26.

[A patient with a wide aorta and 2 wide kidney pelves: retroperitoneal fibrosis].

van Gelder T, Blom JH, de Smit P, Laméris JS, Fieren MW, Schalekamp MA.

Ned Tijdschr Geneeskd. 1991 Jul 13;135(28):1280-2. Dutch.

PMID:
1861766
27.

Involvement of prostaglandins and cytokines in antitumor cytostatic activity of human peritoneal macrophages.

Bonta IL, Ben-Efraim S, Tak C, Fieren MW, van den Bemd GJ.

Adv Prostaglandin Thromboxane Leukot Res. 1991;21B:879-82. No abstract available.

PMID:
1825430
28.
31.
32.

Alterations in sensitivity and secretion of prostaglandins of human macrophages during CAPD-related peritonitis.

Fieren MW, Adolfs MJ, Bonta IL.

Contrib Nephrol. 1987;57:55-62. No abstract available.

PMID:
2824128
33.

Implantation technic for CAPD catheters.

Bijnen AB, Fieren MW, Jeekel J.

Neth J Surg. 1986 Feb;38(1):23. No abstract available.

PMID:
3960368
34.
35.

Infectious-inflammatory environment alters prostaglandin regulation of cyclic AMP levels in human peritoneal macrophages.

Bonta IL, Adolfs MJ, Fieren MW.

Adv Prostaglandin Thromboxane Leukot Res. 1985;15:373-5. No abstract available.

PMID:
3004143
36.

Clinical application of amikacin dosage based upon lean body mass in patients with different renal function.

Wagenvoort JH, Fieren MW, Goessens WH, Michel MF.

Chemotherapy. 1984;30(2):69-75.

PMID:
6697814
37.

Cyclic AMP levels and their regulation by prostaglandins in peritoneal macrophages of rats and humans.

Bonta IL, Adolfs MJ, Fieren MW.

Adv Cyclic Nucleotide Protein Phosphorylation Res. 1984;17:615-20. No abstract available.

PMID:
6328942
38.

Cyclic AMP levels and their regulation by prostaglandins in peritoneal macrophages of rats and humans.

Bonta IL, Adolfs MJ, Fieren MW.

Int J Immunopharmacol. 1984;6(6):547-55.

PMID:
6210257

Supplemental Content

Loading ...
Support Center